A chilling outbreak of meningitis is gripping Kent, prompting urgent action from health officials. Students at the University of Kent in Canterbury are now facing a targeted vaccination program as authorities scramble to contain the spread of this deadly disease.
But for many, this response feels tragically late. Khali Goodwin’s 21-year-old daughter, Keeleigh, is currently recovering in hospital after falling severely ill with meningitis just days ago. Khali’s anger is palpable: “All of this could have been prevented, and two people could still be alive. It is a disgrace. The government didn’t care.”
Keeleigh’s case highlights a painful truth. She, like countless others, was unaware she was vulnerable – never having received the MenB vaccine. The realization that a simple jab could have offered protection has left Khali reeling, demanding accountability and immediate change.
This isn’t an isolated incident. For over a decade, campaigners have relentlessly pleaded with the government to broaden access to the MenB vaccine, extending it beyond infants. A 2016 petition, fueled by the heartbreaking story of two-year-old Faye Burdett and the struggles of rugby player Matt Dawson’s son, became the most-signed on the UK government website.
Despite overwhelming public pressure, the Department of Health repeatedly rejected these calls, citing recommendations from the Joint Committee on Vaccination and Immunisation (JCVI). More recently, a 2024 petition garnered over 40,000 signatures, yet the response remained the same.
Marrissa Mullans knows this frustration all too well. She lost her 18-year-old son, Alfie, to meningitis B in June 2023. Now, she’s a fierce advocate for wider vaccine access. “The current outbreak should not be happening,” she insists. “The vaccine is there and available – it needs to be utilised.”
Alfie, fully vaccinated with routine childhood immunizations, had unknowingly slipped through the cracks. His rapid decline, culminating in cardiac arrest in hospital, spurred Marrissa to launch her own petition, now boasting over 43,000 signatures.
Currently, the MenB vaccine is only routinely administered to infants at eight weeks, 12 weeks, and one year old. Young adults seeking protection must turn to private providers, facing costs upwards of £330 for the complete treatment – a prohibitive expense for many.
The Meningitis Research Foundation has been sounding the alarm for years, consistently urging the government to prioritize better protection for teenagers and young adults. They point to the stark reality that individuals aged 15-24 account for 27% of all MenB cases.
While Health Secretary Wes Streeting has announced a targeted vaccination program for students in Kent, many question whether this is enough. The core issue remains: a systemic failure to protect a vulnerable population. The debate centers on cost-effectiveness, with some experts arguing that expanding the program would be financially unsustainable.
However, for grieving mothers like Khali and Marrissa, the cost of inaction is far greater. They, and countless others, are demanding a future where young lives aren’t needlessly lost to a preventable disease. The outbreak in Kent is not just a public health crisis; it’s a stark reminder of the human cost of delayed decisions.
The question now is whether this crisis will finally force a reevaluation of the current policy, ensuring that all those at risk have access to the protection they deserve.
